Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. April 2026 06:48 ET | Quelle: Research and Markets

Medulloblastoma Drugs Market Analysis and Growth Forecast 2026-2030 & 2035 by Drug Candidate, Product, Route of Administration, Distribution Channel, End-user and Region

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Medulloblastoma Drug Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights, covering...
01. April 2026 13:00 ET | Quelle: DelveInsight Business Research LLP

Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

New York, USA, April 01, 2026 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Developing Drugs for Market Entry |...
01. April 2026 07:05 ET | Quelle: Research and Markets

Automated Cell Processing Systems Market Report 2026-2035: Industry Poised for 16% CAGR Growth Amid Biotechnology Breakthroughs

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Automated Cell Processing System Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Cell Therapy Processing Step, Scale of...
01. April 2026 06:42 ET | Quelle: Research and Markets

Gemcitabine Hydrochloride Market Report 2026-2030 & 2035 Featuring Strategic Analysis of Fresenius Kabi, Eli Lilly and Company, Teva Pharma, Intas Pharma, Mylan and More

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Gemcitabine Hydrochloride Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides detailed statistics on global...
01. April 2026 05:20 ET | Quelle: Research and Markets

Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Advanced Renal Cell Carcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report outlines...
01. April 2026 05:16 ET | Quelle: Research and Markets

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis,...
31. März 2026 16:05 ET | Quelle: Fortress Biotech, Inc.

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205...
31. März 2026 08:30 ET | Quelle: Research and Markets

$4.26 Billion Brain Tumor Drugs Market 2026: Trends and Growth Outlook to 2030 & 2035

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Brain Tumor Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The brain tumor drugs market has witnessed robust...
31. März 2026 07:32 ET | Quelle: Research and Markets

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The "Ovarian Cancer Drugs Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive analysis, covering...
30. März 2026 16:05 ET | Quelle: Fortress Biotech, Inc.

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the closing of...

Vorherige Seite

Nächste Seite